Log in
Enquire now
‌

US Patent 11957688 Combination therapy with apilimod and glutamatergic agents

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
119576880
Patent Inventor Names
Sean Landrette0
Jonathan M. Rothberg0
Henri Lichenstein0
Peter Ronald Young0
Date of Patent
April 16, 2024
0
Patent Application Number
178624710
Date Filed
July 12, 2022
0
Patent Citations
‌
US Patent 7045517 Triazine compounds
0
‌
US Patent 7067514 Pyrimidine compounds
0
‌
US Patent 7470681 Pyrimidine compounds
0
‌
US Patent 7745436 Disalt inhibitors of IL-12 production
0
‌
US Patent 7851466 Pyrimidine compounds and uses thereof
0
‌
US Patent 7863270 IL-12 modulatory compounds
0
‌
US Patent 7919487 Heteroaryl compounds
0
‌
US Patent 7923557 Process for preparing trisubstituted pyrimidine compounds
0
...
Patent Primary Examiner
‌
Raymond J. Henley, III
0
CPC Code
‌
A61K 31/498
0
‌
A61K 31/66
0
‌
A61K 31/675
0
‌
A61K 31/5375
0
Patent abstract

Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11957688 Combination therapy with apilimod and glutamatergic agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.